MDGL Quote, Financials, Valuation and Earnings

Crinetics Pharmaceuticals, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -90972.73%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $635.21, signalling upside risk potential of 27.54%. On the other hand Crinetics Pharmaceuticals, Inc. has an analysts' consensus of $84.50 which suggests that it could grow by 53.78%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.001, which suggesting that the stock is 200.123% less volatile than S&P 500. In comparison Crinetics Pharmaceuticals, Inc. has a beta of 0.196, suggesting its less volatile than the S&P 500 by 80.394%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Crinetics Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Crinetics Pharmaceuticals, Inc. quarterly revenues of $143K. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Crinetics Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 14.91x versus 3,334.61x for Crinetics Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 10.24%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $635.21, signalling upside risk potential of 27.54%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.61%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.001, which suggesting that the stock is 200.123% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 14.91x versus 7.30x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 31.72%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Eli Lilly & Co.'s return on equity of 106.26%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $635.21, signalling upside risk potential of 27.54%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.72 which suggests that it could grow by 2.15%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Madrigal Pharmaceuticals, Inc. has a beta of -1.001, which suggesting that the stock is 200.123% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.55% to investors and pays a quarterly dividend of $1.50 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 14.91x versus 16.68x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 21.32%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Pfizer Inc.'s return on equity of 10.84%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $635.21, signalling upside risk potential of 27.54%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 9.8%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.001, which suggesting that the stock is 200.123% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.59% to investors and pays a quarterly dividend of $0.43 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 14.91x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.